98/393/EC: Commission Decision of 19 May 1998 on financial assistance from the Community for storage in France, Italy and the United Kingdom of antigen for production of foot-and-mouth disease vaccine (notified under document number C(1998) 1365) (Only the English, French and Italian texts are authentic) (Text with EEA relevance)
1. The Community shall grant France financial assistance for the stocking of antigen for production of foot-and-mouth disease vaccine.
2. The 'Laboratoire de pathologie bovine du Centre national d'études vétérinaires et alimentaires` at Lyon in France shall hold the stock of antigen to which paragraph 1 relates. The provisions of Article 4 of Decision 91/666/EEC shall apply.
3. The Community's financial assistance shall be a maximum of ECU 40 000 for the period 1 January to 31 December 1998.
1. The Community shall grant Italy financial assistance for the stocking of antigen for production of foot-and-mouth disease vaccine.
2. The 'Istituto Zooprofilattico Sperimentale di Brescia` in Italy shall hold the stock of antigen to which paragraph 1 relates. The provisions of Article 4 of Decision 91/666/EEC shall apply.
3. The Community's financial assistance shall be a maximum of ECU 40 000 for the period 1 January to 31 December 1998.
1. The Community shall grant the United Kingdom financial assistance for the stocking of antigen for production of foot-and-mouth disease vaccine.
2. The Institute for Animal Health at Pirbright in the United Kingdom shall hold the stock of antigen to which paragraph 1 relates. The provisions of Article 4 of Decision 91/666/EEC shall apply.
3. The Community's financial assistance shall be a maximum of ECU 40 000 for the period 1 January to 31 December 1998.
1. The Community's financial assistance referred to in Article 1(3), Article 2(3) and Article 3(3) shall be paid as follows:
- 70 % by way of an advance at the request of the Member State concerned,
- the balance following presentation, by the Member State concerned, of supporting documents which demonstrate the effective completion of the tasks.
2. The supporting documents referred to in paragraph 1 must be presented to the Commission before 1 March 1999 and they should include:
(a) technical information on:
- the amount and type of antigen stored (storage records),
- storage equipment used (type, number and capacity of tanks),
- security system in place (temperature control, anti-theft measures),
- insurance arrangements (fire, accidents);
(b) financial information (completion of table as shown in the Annex).
Articles 8 and 9 of Regulation (EEC) No 729/70 shall apply mutatis mutandis.
This Decision is addressed to the French Republic, the Italian Republic and the United Kingdom of Great Britain and Northern Ireland.
Done at Brussels, 19 May 1998.
For the Commission
Franz FISCHLER
Member of the Commission
(1) OJ L 224, 18. 8. 1990, p. 19.
(2) OJ L 168, 2. 7. 1994, p. 31.
(3) OJ L 368, 31. 12. 1991, p. 21.
(4) OJ L 94, 28. 4. 1970, p. 13.
(5) OJ L 125, 8. 6. 1995, p. 1.
Supplementary provisions
ANNEXSupplementary provisions
Financial information related to the storage of antigen for production of foot-and-mouth disease vaccine
STATEMENT OF COSTS
>START OF GRAPHIC>
Reporting period from to
Reference No of Commission Decision providing financial assistance:
Name and address of beneficiary: Category of costs Amount for the period (National currency) (1)
1. Staff 2. Capital equipment 3. Consumables 4. Insurance 5. Rental of premises Total (1) All costs must be expressed in national currency.
Certificate by the beneficiary
We certify that:
- the above costs were incurred in connection with the tasks defined in the Decision and were essential to the sound performance of those tasks,
- they are genuine costs falling within the definition of reimbursable costs,
- all the documents supporting the costs are available for audit purposes.
Date:
Name of technical director:
Signature:
Date:
Person financially responsible:
Signature:
>END OF GRAPHIC>
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.
